These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35621628)

  • 1. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.
    Wei T; Ti W; Song Q; Cheng Y
    Curr Oncol; 2022 Apr; 29(5):2920-2927. PubMed ID: 35621628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
    Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
    Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
    Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
    J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 inhibitors plus chemotherapy as first-line therapy for stage IV ESCC.
    Lu J; Qin Z; Ma J; Yao N; Qu W; Cui L; Yuan S; Yao Y
    J Chemother; 2024 May; 36(3):258-263. PubMed ID: 37592822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.
    Zhang T; Guo Z; Chen X; Dong J; Jiang H; Tang P; Wang P; Qian D; Zhang W; Pang Q
    Radiat Oncol; 2022 Aug; 17(1):148. PubMed ID: 35999608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
    Wang LL; Xie YX; Liu Y
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):659-667. PubMed ID: 38305608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.
    Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
    Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
    Lu J; Du L; Lei X; Zhang Z
    Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
    Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
    Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
    Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
    Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
    Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer.
    Ma J; Yao N; Lu J; Qu W; Cui L; Yuan S; Li N; Tong S; Qin Z; Yao Y
    Front Oncol; 2023; 13():1005856. PubMed ID: 36845696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D; Tang L; Hu J; Cao X; He Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
    Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
    Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J
    Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.
    Qiu J; Lin H; Yu Y; Ke D; Li H; Zheng H; Zheng Q; Wang Z; Lin M; Yang J; Liu L; Zhang M; Liu T; Wu Y; Li J; Lai J
    Int J Clin Oncol; 2023 Apr; 28(4):550-564. PubMed ID: 36735115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.